CHOP-Campath
Trial overview
A phase I dose escalation study to establish the maximal tolerated dose of Campath in combination with CHOP and to assess the toxicity of the combination in the primary treatment of peripheral T cell lymphoma (PTCL).
Inclusion criteria
i. Diagnosis of peripheral T cell lymphoma.
- PTCL not otherwise specified (NOS)
- AITL - angioimmunoblastic T cell lymphoma
- ALK negative anaplastic large cell lymphoma
- Intestinal T cell lymphoma
ii. Expression of CD52 by the tumour (central review pre-chemo)
iii. Aged 18 years or older
iv. Bulky stage IA and stages IB-IV (Ann Arbor staging system)
v. WHO performance status ≤2
vi. Measurable or evaluable disease
vii. Written informaed consent obtained
Exclusion criteria
i. ALK+ve anaplastic large cell lymphoma
ii. Presence of other serious, uncontrolled medical conditions
iii. Significant cardiac impairment (anthracycline), LVEF <50%
iv. Creatinine >150μmol/l and/or Bilirubin >2 x normal value unless due to disease
v. Previous malignancy except adequately treated non-melanoma skin cancer or CIN
vi. Previous cytotoxic chemotherapy
vii. Previous radiotherapy may be allowable - discuss with trial coordinator.
viii.CNS involvement with NHL
ix. Positive serology for: HIV, Hepatitis B or C, HTLV1 (or non-consenting to test)
x. Patients who are pregnant or breast feeding.
Contact details
Tags
alemtuzumab campath chop peripheral t cell lymphoma t cell lymphoma ptcl